Clay Shorrock
August 12th, 2024
Recent Posts
- Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
- Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
- Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
- APDN Reminds Shareholders to Vote Ahead of Special Meeting on February 14
- Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
- Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
- Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
- APDN to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
- Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement